Top Industry Leaders in the Parry-Romberg Syndrome Market
Aligos Therapeutics Completed Phase I clinical trials for their investigational gene therapy candidate, AT-007, for the treatment of PRS. These trials demonstrated safety and tolerability, paving the way for further clinical development.Partnered with leading research institutions to advance their understanding of PRS genetics and identify potential therapeutic targets.
Tonix Pharmaceuticals Received FDA Fast Track designation for their investigational drug TNX-102 for the treatment of PRS fatigue, one of the most debilitating symptoms. This designation prioritizes their application review and potentially expedites market access.Conducted Phase II clinical trials evaluating TNX-102's efficacy and safety in PRS patients, with promising preliminary results.
ReNeuron Group Advanced their stem cell therapy candidate, ReN009, for PRS treatment to Phase II clinical trials. This therapy aims to regenerate damaged facial tissues and potentially restore lost volume and function.Collaborated with healthcare providers to expand patient recruitment and accelerate clinical development of ReN009.
Botox (Allergan) Expanded their research to evaluate the potential of botulinum toxin injections for managing chronic pain and facial muscle spasticity associated with PRS.Conducted clinical trials exploring different injection techniques and dosages for optimal pain relief and improved quality of life in PRS patients.
List of Parry-Romberg Syndrome Key companies in the market
- DePuy Synthes (U.S.)
- Johnson & Johnson Services, Inc. (US)
- Medtronic (Ireland)
- Abbott (US)
- Immediate Media Company Ltd. (US)
- Taj Pharmaceuticals Ltd.
- Pfizer, Inc.
- Sanofi-Aventis
- Biogen, Inc.
- GlaxoSmithKline, Inc.
- AstraZeneca plc